Biotech
56 companies in this sector.
| # | Company | Description | Location | Status | Funding |
|---|---|---|---|---|---|
| 01 | Isomorphic Labs | London-based AI-first drug design and development company spun out of Google DeepMind in 2021. Builds the IsoDDE drug design engine leveraging AlphaFold-derived architectures to design therapeutic candidates across disease areas. CEO Demis Hassabis is also CEO of Google DeepMind. | London, United Kingdom | Private | $2.7B |
| 02 | Freenome | Biotech company developing AI-powered multiomics blood tests for early cancer detection. Its platform analyzes cell-free DNA, methylation patterns, and protein biomarkers from routine blood draws to screen for cancers in their earliest stages. Lead product SimpleScreen targets FDA approval for colorectal cancer screening. | South San Francisco, California, United States | Private | $1.3B |
| 03 | SHINE Technologies | Nuclear fusion company commercializing fusion-based technologies through a phased strategy: industrial testing (FLARE neutron source), medical isotopes (Lu-177 for cancer therapy, Mo-99 for diagnostics), nuclear waste recycling, and ultimately fusion energy. The Cassiopeia facility in Janesville, WI is the largest n.c.a. Lu-177 production facility in North America (200,000 doses/year capacity). Achieved first-ever visible Cherenkov radiation produced by fusion in 2023. | Janesville, US | Private | $1.0B |
| 04 | Candid Therapeutics | Candid Therapeutics is a clinical-stage biotechnology company developing novel T-cell engager antibodies to treat autoimmune and inflammatory diseases. The company's platform redirects T-cells to selectively eliminate autoreactive B-cells, with clinical programs spanning five autoimmune indications. Founded by Ken Song after his $4.1B sale of RayzeBio to Bristol Myers Squibb. | San Diego, California, United States | Private | $875M |
| 05 | Ginkgo Bioworks | Synthetic biology company that builds an automated platform for programming cells, enabling customers across pharmaceuticals, agriculture, and industrial chemicals to harness the power of biology. | Boston, US | Public | $720M |
| 06 | Apeel Sciences | Apeel Sciences develops plant-derived, edible coatings that extend the shelf life of fresh produce by slowing water loss and oxidation. Founded with a Bill and Melinda Gates Foundation grant, the company's FDA-approved coatings are made from lipids found in fruit peels, enabling longer freshness without refrigeration. Used by major retailers including Costco, Kroger, and Walmart. | Goleta, United States | Private | $715M |
| 07 | Babylon Health | Babylon Health was a digital healthcare company that used AI to provide virtual consultations, triage, and health monitoring through its mobile app. After partnering with the UK's NHS and expanding globally, the company went public via SPAC at a $4.2 billion valuation in 2021 before collapsing into Chapter 7 bankruptcy in August 2023. | London, United Kingdom | Private | $642M |
| 08 | Science Corp | Neurotechnology company developing a brain-computer interface called Science Eye to restore vision for people with retinal diseases. Uses a thin-film microLED display implanted behind the retina. Founded by Neuralink co-founder Max Hodak. | Alameda, United States | Private | $490M |
| 09 | Benchling | Benchling is a cloud-based life sciences R&D platform that helps biotech and pharmaceutical companies manage experiments, track data, and accelerate research and development. The platform replaces physical lab notebooks and spreadsheets with collaborative, AI-ready digital tools used by over 1,200 customers worldwide. | San Francisco, US | Private | $412M |
| 10 | Cedar | Cedar is a healthcare financial technology platform that simplifies patient billing and payment experiences for hospitals, health systems, and medical groups. The platform uses data science and AI to personalize billing communications and optimize payment outcomes, serving over 50 million patients. | New York, United States | Private | $351M |
| 11 | CellCentric | Cambridge, UK clinical-stage biotech developing inobrodib, a first-in-class oral p300/CBP inhibitor for relapsed/refractory multiple myeloma and other cancers. Based on the science of Azim Surani at the Gurdon Institute, Cambridge. | Cambridge, United Kingdom | Private | $340M |
| 12 | Headway | Headway is a mental health platform building the first national network of therapists who accept insurance. The company handles credentialing, billing, and administrative tasks for therapists, making it easier for patients to find affordable in-network mental health care across all 50 states. | New York, United States | Private | $327M |
| 13 | Oricell Therapeutics | Chinese clinical-stage biotech developing next-generation CAR-T cell therapies for solid tumors. Lead asset Ori-C101 targets hepatocellular carcinoma (liver cancer), aiming to become the first globally-approved CAR-T for the disease. Pipeline focused on overcoming the historical limitations of CAR-T in solid tumors. | Shanghai, China | Private | $270M |
| 14 | Iterative Health | Cambridge, Massachusetts AI-driven healthcare technology and clinical research network (originally Iterative Scopes). Started with computer vision for GI endoscopy and the SKOUT polyp detection system, now expanding into cardiology and obesity clinical trials. | Cambridge, United States | Private | $267M |
| 15 | Accolade | Accolade is a personalized health and benefits solutions company that uses technology, data analytics, and clinical expertise to help employers improve healthcare outcomes while controlling costs. The platform connects employees and families to the right care through AI-powered navigation, virtual primary care (PlushCare), and expert medical opinions (2nd.MD). | Plymouth Meeting, United States | Acquired | $235M |
| 16 | Ray Therapeutics | Clinical-stage biotechnology company developing optogenetic gene therapies to restore vision in patients with blinding retinal diseases. Delivers bioengineered, highly light-sensitive proteins to targeted retinal cells via a single intravitreal injection. Lead program RTx-015 targets retinitis pigmentosa with FDA RMAT designation. Approach is mutation-agnostic, working across many genetic causes of blindness. | Berkeley, United States | Private | $231M |
| 17 | Doctor on Demand | Doctor on Demand was a telehealth platform providing on-demand video visits with board-certified physicians, psychiatrists, and psychologists. In 2021, it merged with Grand Rounds Health to form Included Health, a comprehensive virtual care and navigation platform serving employers and health plans. | San Francisco, United States | Acquired | $223M |
| 18 | Masimo | Global medical technology company that develops noninvasive patient monitoring technologies, including Signal Extraction Technology (SET) pulse oximetry. Innovations address limitations in traditional pulse oximetry by providing accurate readings through patient motion and low perfusion. Products used in hospitals worldwide. | Irvine, US | Private | $203M |
| 19 | Orchestra BioMed | Orchestra BioMed is a biomedical innovation company that accelerates high-impact medical technologies through risk-reward sharing partnerships with leading medical device companies. Its lead programs are BackBeat Cardiac Neuromodulation Therapy for hypertension treatment in pacemaker patients and Virtue Sirolimus AngioInfusion Balloon for atherosclerotic artery disease. The company has strategic partnerships with Medtronic and Terumo Corporation. | New Hope, United States | Public | $185M |
| 20 | Coultreon Biopharma | Belgian immunology biotech (formerly Onco3R Therapeutics) developing COL-5671, an oral SIK3 inhibitor targeting psoriasis and ulcerative colitis. The aim is biologic-class efficacy delivered as a once-daily pill, with the lead asset transferred from Galapagos in 2025. | Leuven, Belgium | Private | $148M |
| 21 | Pinnacle Medicines | Pioneer of oral peptide therapeutics that integrates physics-based molecular simulations, AI-enabled design, and advanced peptide chemistry. Pipeline targeting immunology and cardiometabolic diseases. | Doylestown, United States | Private | $134M |
| 22 | Beacon Biosignals | Combines FDA-cleared wearable EEG technology with advanced AI to capture and analyze real-world neural data, enabling breakthroughs across neurology, psychiatry, and sleep medicine. Building the world's largest neurodiagnostic dataset. Making brain function measurable and actionable at scale. | Boston, United States | Private | $132M |
| 23 | Pardes Biosciences | Clinical-stage biopharmaceutical company that developed novel oral antiviral therapeutics targeting COVID-19. Went public via SPAC merger in 2021 before being acquired by MediPacific (a Foresite Capital affiliate) in 2023 after its lead candidate failed Phase 2 trials. | Carlsbad, US | Acquired | $127M |
| 24 | Cartography Biosciences | Cartography Biosciences is a precision oncology company developing cancer immunotherapies guided by the first comprehensive antigen atlas for immuno-oncology targets. The company's proprietary ATLAS and SUMMIT platforms combine single-cell genomics, proteomics, and computational biology to identify tumor-selective antigens, enabling antibody-based therapies that target tumors more precisely than existing therapeutics. | South San Francisco, United States | Private | $124M |
| 25 | CREATE Medicines | Cambridge, MA clinical-stage biotech (formerly Myeloid Therapeutics) developing in vivo CAR therapies that reprogram immune cells (T cells, NK cells, myeloid cells) inside the body using an mRNA plus lipid nanoparticle delivery platform. Lead program CRT-402 targets CD19 for autoimmune disease. | Cambridge, United States | Private | $122M |
| 26 | Nurx | Telehealth platform providing accessible and affordable healthcare with prescriptions delivered to patients' doors. Started with birth control and PrEP (HIV prevention), then expanded to STI testing, HPV screening, herpes treatment, migraine care, and dermatology. At its peak, Nurx served over 750,000 active patients. Founded by two Norwegian high school classmates who saw how difficult it was to access basic reproductive healthcare. | - | Acquired | $116M |
| 27 | uBiome | uBiome was a biotechnology company that developed technology to sequence and analyze the human microbiome using proprietary machine-learning algorithms. The company offered consumer testing kits and clinical diagnostics (SmartGut, SmartJane) reimbursed by health insurance. uBiome collapsed in 2019 after an FBI raid over healthcare fraud, with its co-founders later indicted for defrauding investors and insurers. | San Francisco, United States | Private | $110M |
| 28 | Crossbow Therapeutics | Biotech developing TCR-mimetic antibody therapies (T-Bolt immunotherapies) to treat cancer. Lead candidate CBX-250 targets myeloid cancers with a Phase 1 trial underway and data expected by end of 2026. | Cambridge, United States | Private | $107M |
| 29 | Stipple Bio | Precision oncology biotech harnessing epitope-level precision to create targeted cancer therapies. The Pointillist Platform identifies tumor-specific cell surface epitopes, enabling antibody-drug conjugates (ADCs) that avoid on-target/off-tumor toxicity. Lead candidate STP-100 expected in clinical studies early 2027. | Cambridge, United States | Private | $100M |
| 30 | Tomorrow Health | Tomorrow Health is a technology-driven home healthcare platform that connects patients, health plans, providers, and suppliers to streamline the ordering, delivery, and management of home-based medical equipment and care. The company works with over 125 health plans and health systems. | New York, United States | Private | $93M |
| 31 | Immutrin | UK biotech developing next-generation antibody therapy to reverse ATTR amyloidosis (amyloid cardiomyopathy). Co-founded by Nobel Laureate Sir Gregory Winter. Novel antibody selectively binds amyloid fibrils to stimulate targeted immune-mediated clearance. | Cambridge, United Kingdom | Private | $87M |
| 32 | R1 Therapeutics | Clinical-stage biopharma developing a first-in-class treatment (AP306) for hyperphosphatemia in chronic kidney disease patients. AP306 is a pan-phosphate transporter inhibitor with a Phase 2b study planned for 2026. | San Francisco, United States | Private | $78M |
| 33 | Kanvas Biosciences | Princeton-based spatial biology company building a microbiome drug discovery, screening, and manufacturing platform. Lead candidate KAN-001 is a live biotherapeutic for solid-tumor patients who do not respond to immune checkpoint inhibitors. Spinout from Cornell, founded 2020. | Princeton, United States | Private | $71M |
| 34 | Notable Labs | Clinical-stage precision oncology company that built a proprietary Predictive Precision Medicines Platform (PPMP) to bio-simulate cancer treatments and predict patient response. Originally tested combinations of FDA-approved drugs on patient cancer cell samples for blood cancers. Demonstrated 84% accuracy in predicting treatment responses with Stanford. | Foster City, United States | Private | $66M |
| 35 | Unnatural Products | Developing orally-delivered macrocyclic peptide therapeutics to address previously undruggable targets. Platform combines parallel experimentation and machine learning, with a Novartis licensing deal worth up to $1.7B in milestones. | Santa Cruz, United States | Private | $62M |
| 36 | NVision | Ulm-based German quantum-tech company hyperpolarizing metabolic molecules to amplify MRI signals roughly 10,000x for real-time disease metabolism imaging. Expanding into quantum computing for drug design. Backed by Abbott as Series B anchor. | Ulm, Germany | Private | $55M |
| 37 | Fathom Therapeutics | AI and quantum chemistry-driven drug discovery company (formerly Atommap). The Microcosmos engine simulates protein dynamics at atomic resolution roughly 10,000x faster than conventional methods, designing small-molecule medicines for historically undruggable targets. | New York, United States | Private | $54M |
| 38 | ClearNote Health | San Diego-based blood-based early cancer detection company (formerly Camera Health). Avantect pancreatic test plus Virtuoso platform for pancreatic and ovarian cancers. Founded 2018. Operating CEO Dave Mullarkey leads commercial expansion; Kevin Keegan newly named President and COO. | San Diego, USA | Private | $52M |
| 39 | Prolium Bioscience | Clinical-stage biotech developing PRO-203, a potential best-in-class CD20xCD3 T-cell engager for severe autoimmune diseases including systemic sclerosis and lupus. | New York, New York, United States | Private | $50M |
| 40 | Inherent Labs | London-based AI-native science lab building Faraday, a system pairing human researchers with self-improving AI agents to identify which scientific questions are worth pursuing. Emerged from stealth May 2026. Founders are ex-DeepMind researchers; Matt Clifford (Entrepreneurs First) is an advisor. | London, United Kingdom | Private | $50M |
| 41 | Triomics | New York-based oncology-specific AI for cancer centers. Powers clinical trial matching and chart abstraction at MSK, MD Anderson, Yale/Smilow, and Mount Sinai Tisch. Founded 2021 with operations in India. | New York, USA | Private | $37M |
| 42 | Human API | Human API is a consumer-controlled health data platform that connects to electronic health record networks, patient portals, pharmacies, labs, wearable devices, and fitness apps through a single secure API. The platform converts health data into actionable intelligence, primarily serving life insurance underwriting, clinical research, and digital health companies. | San Mateo, United States | Acquired | $37M |
| 43 | Techcyte | Orem, Utah AI-powered digital pathology platform (Fusion) serving human medical, veterinary, and environmental laboratories. Integrates AI with digitized lab workflows for diagnostic accuracy across cytology, hematology, and parasitology. | Orem, United States | Private | $36M |
| 44 | Waypoint Bio | New York-based AI-native biotech using spatial pooled screening and computer vision to design in vivo CAR T therapies for solid tumors. Lead program WAY-103. Founded 2021. CTO Patrick Kaifosh previously at CTRL-Labs and Meta Reality Labs. | New York, USA | Private | $35M |
| 45 | Waiv | AI precision testing company spun out from Owkin, applying deep neural network analysis to digitized biopsy slides for oncology biomarker discovery, detection, and treatment-response prediction | Paris, France | Private | $33M |
| 46 | Secretome Therapeutics | Plano, Texas-based neonatal cardiac progenitor-cell (nCPC) therapy company (formerly NeoProgen). Lead asset STM-01 targets Duchenne muscular dystrophy-associated cardiomyopathy. Founded 2018. | Plano, USA | Private | $30M |
| 47 | P2 Science | Connecticut-based green chemistry company converting plant oils and sustainable feedstocks into ingredients for beauty, aroma, polymers, coatings, and crop care. Founded 2009 by Yale Center for Green Chemistry scientists. CEO Oihana Elizalde leads commercial scale-up. | Woodbridge, USA | Private | $23M |
| 48 | Modern Fertility | Women's health company that made fertility hormone testing accessible and affordable through at-home testing kits. The flagship product measured up to 10 fertility hormones via a simple finger-prick, providing personalized reports and fertility timelines. Expanded into ovulation tracking kits, pregnancy tests, and prenatal vitamins. Founded by a former 23andMe product lead after a personal health scare revealed the gap in accessible fertility information. | - | Acquired | $22M |
| 49 | StrainX Bioworks | Bhopal-based Indian synthetic biology company using precision fermentation to produce alternative proteins, nutrition ingredients, materials, and consumer health products at scale. 10,000-liter fermentation demonstrated; targeting 100,000-liter commercial operations. | Bhopal, India | Private | $13M |
| 50 | Perceptic | London-based AI operating system for drug discovery and clinical development covering asset scouting, scientific evaluation, indication selection, and clinical data analysis. Deployed at top-20 pharma including CSL. Founded 2024 by ex-Palantir AIP and Life Sciences leaders. | London, United Kingdom | Private | $12M |
| 51 | Veritas Aortic Solutions | Costa Mesa, California-based developer of the Transcatheter Valved Aortic Root Conduit (TVARC), a catheter-based non-surgical alternative for aortic root and ascending aortic disease. Spun out of inQB8 Medical Technologies in 2024. | Costa Mesa, USA | Private | $12M |
| 52 | Coefficient Bio | Stealth biotech AI startup using AI to accelerate drug discovery and biological research. Founded by former Genentech Prescient Design computational biology researchers. Acquired by Anthropic in April 2026 for $400M, barely 8 months after founding. Team of fewer than 10 people integrated into Anthropic's healthcare and life sciences division. | San Francisco, United States | Acquired | $5M |
| 53 | Acurion | Precision oncology technology company developing advanced diagnostic and therapeutic tools for cancer treatment. Combines AI-driven analysis with clinical workflows to enable personalized cancer care at scale. | San Diego, United States | Private | $4M |
| 54 | Danaher | Global life sciences and diagnostics conglomerate operating three divisions: Biotechnology, Life Sciences, and Diagnostics. Known for the Danaher Business System (DBS), a continuous improvement methodology. Grew through strategic acquisitions including the $5.7 billion purchase of Abcam in 2023. | Washington, US | Private | - |
| 55 | Worldwide Clinical Trials | Global clinical research organization (CRO) providing drug development and clinical trial services across multiple therapeutic areas. Backed by Kohlberg & Company since 2023. | Durham, US | Private | - |
| 56 | Catalyst Clinical Research | Specialized multi-therapeutic functional service provider (FSP) and niche oncology CRO for biopharmaceutical and biotechnology companies. Known for expertise in early phase oncology trials. | Wilmington, US | Acquired | - |